A-TAP - Arthritis Therapy Acceleration Programme
The Arthritis Therapy Acceleration Programme (A-TAP) is an exciting new £7M concept funded by the Kennedy Trust for Rheumatology Research. It brings together the Universities of Birmingham and Oxford and seven NHS partners and is supported by our access to over 7million patients. The initiative is aiming to support and develop novel treatments for arthritis based on the underlying causes of inflammatory disease.
This ambition is facilitated by our innovative new approach to translational inflammation research through our application of unique rigorous signal seeking experimental medicine studies leading to rapid adoption into clinical trials underpinned by novel trial design. The results will help us treat the cause of disease not just their symptoms and help develop a new taxonomy of disease that moves away from a traditional “organ-based, speciality-focussed” approach to a process-driven, pathway-focussed classification for inflammatory diseases.
Latest news from the Kennedy Institute
4 February 2021
New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.
15 January 2021
The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.
18 December 2020
A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults
18 December 2020
In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.